Last updated 4 days ago

Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

240 patients around the world
Available in Argentina, United States
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
4Research sites
240Patients around the world
This study is for people with
Myasthenia gravis
Myasthenia gravis in adults
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Sites
Hospital Córdoba
Recruiting
Avenida Patria 656, Córdoba
Fundación Rosarina de Neuro-Rehabilitación - Rosario, Santa Fe
Recruiting
L. N. Alem 1416, Rosario, Santa Fe
INECO Neurociencias Oroño - Rosario
Recruiting
Bv. Oroño 1508, Rosario, Santa Fe
Centro de Investigaciones Médicas Tucumán
Recruiting
Lavalle 506, T4000 San Miguel de Tucumán, Tucumán, Argentina
Trialtech
About usOur missionOur teamPartnersFAQs
Medical newsLatest newsStudiesInterviewsTestimonials
ProductsUEPM OncoUEPM Physicians
LinksDownloads
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy